{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03557281: Phase 2 Interventional Completed Tuberculosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04546009: Phase 3 Interventional Active, not recruiting Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03261947: Phase 2 Interventional Completed Metastatic Pancreatic Cancer
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01524237: Phase 1 Interventional Completed Healthy Volunteers
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00274716: Phase 2 Interventional Completed Hypertension
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gadomelitol (P792, Vistarem) is a monogadolinated contrast agent for magnetic resonance imaging (MRI) that originally was developed as a blood pool agent with rapid clearance and mainly free renal elimination. Gadomelitol could provide information on the interstitial fluid pressure (negatively associated with disease-free survival in locally advanced cervical carcinoma) of cervical carcinoma xenografts. Due to its slow extravasation and high tumor residence time, gadomelitol may potentially be useful to improve characterization between benign versus malignant tumors using dynamic MRI.
Status:
Investigational
Source:
NCT03025308: Phase 3 Interventional Active, not recruiting Rheumatoid Arthritis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.
Status:
Investigational
Source:
NCT01658020: Phase 3 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.
Status:
Investigational
Source:
NCT01658020: Phase 3 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.
Status:
Investigational
Source:
NCT01658020: Phase 3 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.
